Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it expects to receive ¥0.08 million in funding from Trans Genic Inc.
March 18, 2018
Share
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced a private placement of 2,000 common shares for gross proceeds of ¥80,000 on March 19, 2018. The transaction will include participation from a returning investor, Trans Genic Inc. As part of the transaction, Trans Genic Inc. will acquire 9.7% stake in the company, increasing its stake from 33.3% to 43%. The transaction will take place through third party capital increase. The transaction was approved by the board of directors of Trans Genic Inc. The share acquisition date is April 2, 2018.
TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.
TRANS GENIC INC. 
